astria therapeutics glp-1 receptor agonist weight management diabetes treatments cardinal health GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon glp-1_analogs [TUSOM | Pharmwiki]

Even patients who initially access treatment through coverage may face interruptions if policies change, if prior authorizations are denied, or if employers revise benefits

Key mechanisms of GIP receptor activation include: Amplifying insulin secretion in response to glucose

FDA-approved for chronic weight management

The past several decades have been boom times for innovation across multiple CVD risk factors, bringing forth an abundance of medications to regulate lipids, control blood pressure, lower blood sugar and improve inflammation

10.1016/j.pmn.2022.05.005 [DOI] [PubMed] [Google Scholar] 79.Pandey S, Mangmool S, Madreiter-Sokolowski CT, Wichaiyo S, Luangmonkong T, Parichatikanond W (2023) Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling

These drugs have also caused new or worsening kidney disease, including kidney failure, in some people